Trillium Therapeutics (TRIL) Short Interest Ratio & Short Volume → Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (From Colonial Metals) (Ad) Free TRIL Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Short InterestStock Analysis Trillium Therapeutics Short Interest DataCurrent Short Volume2,220,000 sharesPrevious Short Volume2,310,000 sharesChange Vs. Previous Month-3.90%Dollar Volume Sold Short$40.20 millionShort Interest Ratio / Days to Cover0.8Last Record DateOctober 29, 2021Outstanding Shares104,995,000 sharesFloat Size75,610,000 sharesShort Percent of Float2.94%Today's Trading Volume8 sharesAverage Trading Volume1,866,404 sharesToday's Volume Vs. Average0% Short Selling Trillium Therapeutics ? Sign up to receive the latest short interest report for Trillium Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatTRIL Short Interest Over TimeTRIL Days to Cover Over TimeTRIL Percentage of Float Shorted Over Time Ad Crypto Swap ProfitsClaim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.Secure Your Spot Now Trillium Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 10/29/20212,220,000 shares $40.20 million -3.9%2.9%0.8 $18.11 10/15/20212,310,000 shares $40.43 million -3.4%3.1%0.8 $17.50 9/30/20212,390,000 shares $41.97 million -15.0%3.2%0.9 $17.56 9/15/20212,810,000 shares $48.98 million -6.3%3.7%1 $17.43 8/31/20213,000,000 shares $51.69 million -50.6%4.0%1.1 $17.23 8/13/20216,070,000 shares $37.82 million -1.5%8.0%2.8 $6.23 Get the Latest News and Ratings for TRIL and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Trillium Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 7/30/20216,160,000 shares $40.22 million -21.7%7.9%5.5 $6.53 7/15/20217,870,000 shares $61.39 million -45.0%9.7%5.7 $7.80 6/30/202114,320,000 shares $138.90 million +44.8%18.0%10.3 $9.70 6/15/20219,890,000 shares $93.16 million +3.8%12.4%8 $9.42 5/28/20219,530,000 shares $75.95 million -9.2%12.0%7.6 $7.97 5/14/202110,490,000 shares $88.64 million -1.5%13.2%7.8 $8.45 4/30/202110,650,000 shares $96.60 million +0.6%13.3%7.7 $9.07 4/15/202110,590,000 shares $108.44 million +15.0%13.3%8.1 $10.24 3/31/20219,210,000 shares $94.22 million +3.4%11.6%6.9 $10.23 3/15/20218,910,000 shares $107.19 million +8.4%11.2%5.9 $12.03 2/26/20218,220,000 shares $94.12 million -7.6%10.4%4.1 $11.45 2/12/20218,900,000 shares $117.75 million -7.7%11.2%4.5 $13.23 1/29/20219,640,000 shares $123.87 million -5.5%12.1%4.7 $12.85 1/15/202110,200,000 shares $152.69 million +0.1%12.8%5.1 $14.97 12/31/202010,190,000 shares $136.75 million +4.3%12.8%5.2 $13.42 12/15/20209,770,000 shares $115.77 million +29.8%12.3%5 $11.85 11/30/20207,530,000 shares $148.12 million +26.8%9.5%2.9 $19.67 11/15/20205,940,000 shares $92.07 million +53.9%7.5%2.6 $15.50 10/30/20203,860,000 shares $49.49 million +5.2%4.8%1.8 $12.82 10/15/20203,670,000 shares $54.94 million -17.5%4.6%1.7 $14.97 9/30/20204,450,000 shares $63.23 million -2.8%5.6%2.1 $14.21 9/15/20204,580,000 shares $67.19 million +55.3%5.8%2.2 $14.67 8/31/20202,950,000 shares $33.42 million -7.2%3.7%1.6 $11.33 8/14/20203,180,000 shares $27.83 million +26.7%4.2%2.2 $8.75 7/31/20202,510,000 shares $16.77 million +0.8%3.4%1.5 $6.68 7/15/20202,490,000 shares $18.33 million -58.8%3.4%1.3 $7.36 6/30/20206,040,000 shares $48.86 million -4.7%8.3%3 $8.09 6/15/20206,340,000 shares $52.37 million +8.4%8.7%3 $8.26 5/29/20205,850,000 shares $39.66 million -5.2%8.0%2.4 $6.78 5/15/20206,170,000 shares $35.97 million +22.7%8.5%2.1 $5.83 4/30/20205,030,000 shares $23.34 million -4.9%6.8%1.8 $4.64 4/15/20205,290,000 shares $23.43 million -9.0%7.4%1.7 $4.43 3/31/20205,810,000 shares $28.93 million +45.6%8.1%1.2 $4.98 3/13/20203,990,100 shares $15.80 million +425.8%6.2%0.8 $3.96Claim Your Complimentary Bitcoin Reward (Ad)Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.Secure Your Spot Now TRIL Short Interest - Frequently Asked Questions What is Trillium Therapeutics' current short interest? Short interest is the volume of Trillium Therapeutics shares that have been sold short but have not yet been closed out or covered. As of October 29th, investors have sold 2,220,000 shares of TRIL short. 2.94% of Trillium Therapeutics' shares are currently sold short. Learn More on Trillium Therapeutics' current short interest. What is a good short interest ratio for Trillium Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. TRIL shares currently have a short interest ratio of 1.0. Learn More on Trillium Therapeutics's short interest ratio. What is a good short interest percentage for Trillium Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 2.94% of Trillium Therapeutics' floating shares are currently sold short. Is Trillium Therapeutics' short interest increasing or decreasing? Trillium Therapeutics saw a decrease in short interest in October. As of October 29th, there was short interest totaling 2,220,000 shares, a decrease of 3.9% from the previous total of 2,310,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Trillium Therapeutics' float size? Trillium Therapeutics currently has issued a total of 104,995,000 shares. Some of Trillium Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Trillium Therapeutics currently has a public float of 75,610,000 shares. How does Trillium Therapeutics' short interest compare to its competitors? 2.94% of Trillium Therapeutics' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to Trillium Therapeutics: Galapagos NV (2.18%), Maravai LifeSciences Holdings, Inc. (4.79%), PTC Therapeutics, Inc. (13.39%), NewAmsterdam Pharma (0.86%), Geron Co. (8.53%), Keros Therapeutics, Inc. (5.82%), Amphastar Pharmaceuticals, Inc. (10.63%), Avidity Biosciences, Inc. (12.52%), Schrödinger, Inc. (8.63%), Agios Pharmaceuticals, Inc. (12.06%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: S&P Global Inc. ($8.61 billion), Advanced Micro Devices, Inc. ($8.44 billion), Charter Communications, Inc. ($5.26 billion), Canadian Pacific Kansas City Limited ($5.13 billion), Wayfair Inc. ($4.34 billion), Uber Technologies, Inc. ($3.69 billion), Palo Alto Networks, Inc. ($3.35 billion), Teladoc Health, Inc. ($3.11 billion), eBay Inc. ($2.91 billion), and Etsy, Inc. ($2.63 billion). View all of the most shorted stocks. What does it mean to sell short Trillium Therapeutics stock? Short selling TRIL is an investing strategy that aims to generate trading profit from Trillium Therapeutics as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Trillium Therapeutics? A short squeeze for Trillium Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of TRIL, which in turn drives the price of the stock up even further. How often is Trillium Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including TRIL, twice per month. The most recent reporting period available is October, 29 2021. More Short Interest Resources from MarketBeat Related Companies: Galapagos Short Interest Maravai LifeSciences Short Interest PTC Therapeutics Short Interest NewAmsterdam Pharma Short Interest Geron Short Interest Keros Therapeutics Short Interest Amphastar Pharmaceuticals Short Interest Avidity Biosciences Short Interest Schrödinger Short Interest Agios Pharmaceuticals Short Interest Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:TRIL) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarThe A.I. story nobody is telling you (Read ASAP)TradeSmithRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldHe Is Giving Away BitcoinCrypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyYour Money is Not SafeAmerican Alternative